ClinicalTrials.gg

Program

gemigliptin

Also written as “Gemigliptin”, “Gemigliptin 50mg” and “gemigliptin/metformin HCl extended release”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.

Furthest: phase 4, since May 24, 201330 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LG Chem290 open or runningphase 4since May 24, 2013Oct 21, 2009none ahead
Stendhal Americas10 open or runningphase 1since Sep 13, 2017Sep 13, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Oct 21, 2009.

  1. Feb 5, 2014Phase 1 study in HealthyLG Chem · NCT02056600 · 24 enrolled · Korea, Republic of
  2. Mar 4, 20142 phase 3 studies in Diabetes Mellitus, Type 2LG Chem · NCT02126358, NCT02089126
  3. Dec 22, 20152 phase 1 studies in HealthyLG Chem · NCT02670070, NCT02670018
  4. Jun 23, 2016Phase 3 study in Diabetes Mellitus, Type 2LG Chem · NCT02831361 · 290 enrolled
  5. Jun 26, 2017Phase 4 study in Diabetes Mellitus, Type 2LG Chem · NCT03202563 · 71 enrolled · Korea, Republic of
  6. Sep 13, 2017Stendhal Americas's first study: phase 1 study in Diabetes Mellitus, Type 2New to Stendhal AmericasStendhal Americas · NCT03310749 · 34 enrolled · Mexico
  7. Nov 9, 2017Phase 1 study in Healthy Male VolunteersLG Chem · NCT03355014 · 70 enrolled · Korea, Republic of
  8. May 24, 2018Phase 1 study in Diabetes Mellitus, Type 2LG Chem · NCT03565458 · 48 enrolled · Korea, Republic of
  9. Feb 13, 2019Phase 3 study in Diabetes Mellitus, Type 2LG Chem · NCT03842267 · 315 enrolled · Korea, Republic of
  10. Mar 4, 2019Phase 1 study in Diabetes Mellitus, Type 2LG Chem · NCT03864432 · 48 enrolled · China
  11. Aug 21, 2019Phase 1 study in Type2 DiabetesLG Chem · NCT04070794 · 24 enrolled
  12. Feb 2, 2020Phase 3 study in Diabetes Mellitus, Type 2LG Chem · NCT04255238 · 468 enrolled
  13. Jul 29, 2020Phase 1 study in T2DMLG Chem · NCT04544319 · 44 enrolled
  14. Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea

TargetBeta

DPP4 →read by rule
“An orally bioavailable inhibitor of the serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic and potential renoprotective activities”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
LinagliptinruleBoehringer Ingelheimphase 496
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07399470Healthy Volunteers · South Korea1CompletedLG ChemFeb 6, 202658
NCT04544319T2DM1UNKNOWNLG ChemMar 202144
NCT04255238Diabetes Mellitus, Type 23UNKNOWNLG ChemMay 30, 2022468
NCT04070794Type2 Diabetes1UNKNOWNLG ChemNov 30, 201924
NCT03864432Diabetes Mellitus, Type 2 · China1CompletedLG ChemOct 3, 201948
NCT03842267Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedLG ChemMay 20, 2021315
NCT03565458Diabetes Mellitus, Type 2 · Korea, Republic of1UNKNOWNLG ChemAug 20, 201848
NCT03355014Healthy Male Volunteers · Korea, Republic of1CompletedLG ChemJan 12, 201870
NCT03310749Diabetes Mellitus, Type 2 · Mexico1CompletedStendhal AmericasMay 3, 201634
NCT03202563Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedLG ChemJul 13, 201871
NCT02831361Diabetes Mellitus, Type 23CompletedLG ChemFeb 8, 2018290
NCT02670070Healthy · Korea, Republic of1UNKNOWNLG ChemApr 201637
NCT02670018Healthy · Korea, Republic of1UNKNOWNLG ChemDec 201525
NCT02089126Diabetes Mellitus, Type 2 · Korea, Republic of3UNKNOWNLG ChemSep 2016230
NCT02126358Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedLG ChemMar 2016290
NCT02056600Healthy · Korea, Republic of1CompletedLG ChemApr 201424
NCT01990469Diabetes Mellitus, Type 23CompletedLG ChemApr 2015219
NCT02004587Hepatic Impairment · Germany1CompletedLG ChemMay 201428
NCT01968044Renal Insufficiency · Korea, Republic of3CompletedLG ChemOct 2015132
NCT01890629Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedLG ChemAug 201469
NCT01825850Healthy · Korea, Republic of1CompletedLG ChemSep 201330
NCT01787396Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedLG ChemMar 2015433
NCT01768455Healthy · Korea, Republic of1CompletedLG ChemApr 201327
NCT01662674Healthy · Korea, Republic of1CompletedLG ChemNov 201227
NCT01603238Healthy · Korea, Republic of1CompletedLG ChemMay 20116
NCT01602003Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedLG ChemJun 2011425
NCT01601990Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedLG ChemMar 2011189
NCT01595880Healthy · Korea, Republic of1CompletedLG ChemJan 201529
NCT01426399Healthy · Korea, Republic of1CompletedLG ChemNov 201130
NCT01001013Healthy · Korea, Republic of1CompletedLG ChemJun 200924

How it is read

Names in the registry

  • “Gemigliptin”, 7 entries
  • “Gemigliptin 50mg”, 5 entries
  • “gemigliptin/metformin HCl extended release”, 3 entries
  • “gemigliptin and metformin HCl extended release”, 3 entries
  • “LC15-0444 50mg qd”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.